TMC Life Optimistic About Growth Through Partnerships In 2025
TMC Life Optimistic About Growth Through Partnerships In 2025
TMC Life Sciences Bhd, a leading player in the healthcare industry, achieved significant growth in the financial year ending 30 June 2024 (FY2023/24), focusing on enhancing services for women and children to capitalise on the robust growth in FY2024/25, according to a press statement circulated by the company.
根据该公司发布的新闻声明,医疗保健行业的领先企业TMC Life Sciences Bhd在截至2024年6月30日的财政年度(FY2023/24)中实现了显著增长,专注于加强对妇女和儿童的服务,以利用2024/25财年的强劲增长。
Profit before tax increased by 29% to RM52.6 million year-on-year for FY2023/24. In line with this positive performance and in conjunction with Celebrating Life for 30 years, the board of directors has recommended a final single-tier dividend of 0.4898 sen per ordinary share.
2023/24财年税前利润同比增长29%,达到5260万令吉。董事会建议将每股普通股每股0.4898仙的最终单级股息与这一积极表现一致,并与Celebrating Life合作了30年。
During the group's 22nd Annual General Meeting (AGM) today, Chairman Y Bhg Datuk Sri Mohd Mokhtar bin Mohd Shariff highlighted the group's strong financial position, reporting RM188.6 million in cash and bank balances for FY2023/24, a 13% year-on-year increase. .
在今天的集团第22届年度股东大会(AGM)上,董事长Y Bhg Datuk Sri Mohd Mokhtar bin Mohd Shariff强调了该集团强劲的财务状况,报告称,2023/24财年的现金和银行余额为18860万令吉,同比增长13%。
Acting group CEO, meanwhile, Dr Melvin Heng Jun Li, expressed strong optimism for FY2024/25.
同时,集团代理首席执行官李恒军博士对2024/25财年表示强烈乐观。
Key highlights from FY2023/24 include the successful partnership between Thomson Hospital Kota Damansara (Thomson) and OncoCare Medical Malaysia Sdn Bhd
2023/24 财年的主要亮点包括哥打白沙罗汤姆森医院(汤姆森)与 OncoCare Medical Malaysia Sdn Bhd 之间的成功合作
This collaboration, established on Sept 5, 2024, enhances the Thomson's oncology offerings, showcasing TMCLS's dedication to advancing cancer care.
这项合作建立于2024年9月5日,旨在增强汤姆森的肿瘤学产品,展示了TMCLS对推进癌症治疗的承诺。
Notably, Thomson made history in July 2023 by becoming the first hospital in Southeast Asia to administer the US-approved Spinraza for Spinal Muscular Atrophy. Additionally, the hospital also performed its first bowel atresia surgery on a premature infant in April 2024,
demonstrating a commitment to pioneering medical procedures.
值得注意的是,汤姆森在2023年7月创造了历史,成为东南亚第一家使用美国批准的脊髓性肌萎缩症Spinraza的医院。此外,该医院还于2024年4月对一名早产儿进行了首次肠道闭锁手术,
表明了对开创性医疗程序的承诺。
Looking ahead, TMC Life is strategically poised to capitalise on growth opportunities in the region, driven by increased capacity at Thomson and a resurgence in the fertility business through TMC Fertility. Additionally, a promising uptick in medical tourism further
enhances the group's potential for success.
展望未来,在汤姆森产能增加以及TMC Fertility生育业务复苏的推动下,TMC Life已做好战略准备,抓住该地区的增长机会。此外,医疗旅游业有望进一步增长
增强了集团的成功潜力。
TMC Life is also committed to addressing climate change, with initiatives designed to achieve Net Zero by 2050. The group's dedication to sustainable practices aligns with its ongoing efforts to expand its footprint in the healthcare sector.
TMC Life还致力于应对气候变化,其举措旨在到2050年实现净零排放。该集团对可持续实践的承诺与其为扩大其在医疗保健领域的足迹所做的持续努力相吻合。